Join Growin Stock Community!

Bicycle therapeutics plcBCYC.US Overview

US StockHealthcare
(No presentation for BCYC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BCYC AI Insights

BCYC Overall Performance

BCYC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BCYC Recent Performance

-1.48%

Bicycle therapeutics plc

0.05%

Avg of Sector

-0.31%

S&P500

BCYC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BCYC Key Information

BCYC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BCYC Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Price of BCYC

BCYC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BCYC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.62
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14.03
PB Ratio
0.63
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-884.51%
Revenue Growth (YoY)
-23.20%
Profit Growth (YoY)
-23.20%
3-Year Revenue Growth
56.86%
3-Year Profit Growth
56.86%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.62
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14.03
PB Ratio
0.63
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-884.51%
Revenue Growth (YoY)
-23.20%
Profit Growth (YoY)
-23.20%
3-Year Revenue Growth
56.86%
3-Year Profit Growth
56.86%

  • When is BCYC's latest earnings report released?

    The most recent financial report for Bicycle therapeutics plc (BCYC) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCYC's short-term business performance and financial health. For the latest updates on BCYC's earnings releases, visit this page regularly.

  • What is the operating profit of BCYC?

    According to the latest financial report, Bicycle therapeutics plc (BCYC) reported an Operating Profit of -65.55M with an Operating Margin of -558.64% this period, representing a decline of 2.67% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BCYC's revenue growth?

    In the latest financial report, Bicycle therapeutics plc (BCYC) announced revenue of 11.73M, with a Year-Over-Year growth rate of 338.49%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does BCYC have?

    At the end of the period, Bicycle therapeutics plc (BCYC) held Total Cash and Cash Equivalents of 648.33M, accounting for 0.85 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BCYC go with three margins increasing?

    In the latest report, Bicycle therapeutics plc (BCYC) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -558.64%%, and net margin of -503.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BCYC's profit trajectory and future growth potential.

  • Is BCYC's EPS continuing to grow?

    According to the past four quarterly reports, Bicycle therapeutics plc (BCYC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.85. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BCYC?

    Bicycle therapeutics plc (BCYC)'s Free Cash Flow (FCF) for the period is -71.85M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 78.43% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BCYC?

    The latest valuation data shows Bicycle therapeutics plc (BCYC) has a Price-To-Earnings (PE) ratio of -2.42 and a Price/Earnings-To-Growth (PEG) ratio of 0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.